Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

Location as Destiny: Identifying Geospatial Disparities in Radiation Treatment Interruption by Neighborhood, Race, and Insurance.

Wakefield DV, Carnell M, Dove APH, Edmonston DY, Garner W, Hubler A, Makepeace L, Hanson R, Ozdenerol E, Chun S, Spencer S, Pisu M, Martin M, Jiang B, Punglia RS, Schwartz DL.

Int J Radiat Oncol Biol Phys. 2020 Mar 29. pii: S0360-3016(20)30940-8. doi: 10.1016/j.ijrobp.2020.03.016. [Epub ahead of print]

PMID:
32234552
2.

Online Pro-Tobacco Marketing Exposure Is Associated With Dual Tobacco Product Use Among Underage US Students.

Marion H, Garner W, Estrada A, Moorer C Jr, Acosta-Velazquez I.

Am J Health Promot. 2020 Feb 25:890117120905231. doi: 10.1177/0890117120905231. [Epub ahead of print]

PMID:
32096411
3.

The State of Burn Care Training During Plastic Surgery Residency.

Vrouwe SQ, Pham CH, Minasian RA, Yenikomshian HA, Garner WL, Gillenwater TJ.

Ann Plast Surg. 2020 Feb 7. doi: 10.1097/SAP.0000000000002267. [Epub ahead of print]

PMID:
32039995
4.

Re: Combination therapy for Toxic Epidermal Necrolysis: It is time for anti-TNFa biologics comparison.

Pham CH, Gillenwater TJ, Garner WL.

Burns. 2020 Feb;46(1):245-246. doi: 10.1016/j.burns.2019.11.011. Epub 2019 Dec 18. No abstract available.

PMID:
31862281
5.

Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention.

Van Epps P, Wilson BM, Garner W, Beste LA, Maier MM, Ohl ME.

J Acquir Immune Defic Syndr. 2019 Dec 15;82(5):427-430. doi: 10.1097/QAI.0000000000002186.

PMID:
31714421
6.

Radiosurgery for mesial temporal lobe epilepsy following ROSE trial guidelines - A planning comparison between Gamma Knife, Eclipse, and Brainlab.

Narayanasamy G, Morrill S, Cousins D, Liu J, Deshazer G, Garner W, Galhardo E, Serletis D, Penagaricano J.

J Appl Clin Med Phys. 2019 Oct;20(10):134-141. doi: 10.1002/acm2.12724. Epub 2019 Sep 18.

7.

'Kool Mixx' remix: How Al Capone cigarillos infiltrated Hip-Hop to promote cigarillos use among African-Americans.

Garner W, Brock B, Seth E.

Tob Control. 2019 Sep 6. pii: tobaccocontrol-2018-054816. doi: 10.1136/tobaccocontrol-2018-054816. [Epub ahead of print] No abstract available.

PMID:
31492722
8.

Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.

Pham CH, Gillenwater TJ, Nagengast E, McCullough MC, Peng DH, Garner WL.

Burns. 2019 Nov;45(7):1634-1638. doi: 10.1016/j.burns.2018.12.018. Epub 2019 Aug 26.

PMID:
31466921
9.

Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen.

Rizzardini G, Gori A, Miralles C, Olalla J, Molina JM, Raffi F, Kumar P, Antinori A, Ramgopal M, Stellbrink HJ, Das M, Chu H, Ram R, Garner W, Shao Y, Chuck SK, Piontkowsky D, Haubrich RH.

AIDS. 2019 Aug 1;33(10):1583-1593. doi: 10.1097/QAD.0000000000002244.

PMID:
31305329
10.

Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.

Acosta RK, Willkom M, Martin R, Chang S, Wei X, Garner W, Lutz J, Majeed S, SenGupta D, Martin H, Quirk E, White KL.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02533-18. doi: 10.1128/AAC.02533-18. Print 2019 May.

11.

Health Behaviors and Lifestyle Interventions in African American Breast Cancer Survivors: A Review.

Paxton RJ, Garner W, Dean LT, Logan G, Allen-Watts K.

Front Oncol. 2019 Jan 22;9:3. doi: 10.3389/fonc.2019.00003. eCollection 2019. Review.

12.

Do Websites Provide What Applicants Need? Plastic Surgery Residency Program Websites Versus Applicant Self-reported Needs.

Chen VW, Hoang D, Garner W.

Plast Reconstr Surg Glob Open. 2018 Oct 2;6(10):e1900. doi: 10.1097/GOX.0000000000001900. eCollection 2018 Oct.

13.

Gaps in Preexposure Prophylaxis Uptake for HIV Prevention in the Veterans Health Administration.

Garner W, Wilson BM, Beste L, Maier M, Ohl ME, Van Epps P.

Am J Public Health. 2018 Nov;108(S4):S305-S310. doi: 10.2105/AJPH.2018.304788.

14.

How long are burn patients really NPO in the perioperative period and can we effectively correct the caloric deficit using an enteral feeding "Catch-up" protocol?

Pham CH, Collier ZJ, Webb AB, Garner WL, Gillenwater TJ.

Burns. 2018 Dec;44(8):2006-2010. doi: 10.1016/j.burns.2018.07.005. Epub 2018 Aug 14.

PMID:
30115532
15.

Linezolid-Induced Leukocytoclastic Vasculitis.

Kruzer K, Garner W, Honda K, Packer CD.

Ann Pharmacother. 2018 Dec;52(12):1263-1264. doi: 10.1177/1060028018793246. Epub 2018 Aug 1. No abstract available.

PMID:
30066575
17.

Measuring gastric residual volumes in critically ill burn patients - A systematic review.

Pham CH, Collier ZJ, Garner WL, Kuza CM, Gillenwater TJ.

Burns. 2019 May;45(3):509-525. doi: 10.1016/j.burns.2018.05.011. Epub 2018 Jun 18.

PMID:
29914737
18.

Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trials.

White K, Garner W, Wei L, Eron JJ, Zhong L, Miller MD, Martin H, Plummer A, Tran-Muchowski C, Lindstrom K, Porter J, Piontkowsky D, Light A, Reiske H, Quirk E.

AIDS. 2018 May 15;32(8):1053-1057. doi: 10.1097/QAD.0000000000001779.

PMID:
29424783
19.

Health Inequity And Civil Rights Laws.

Garner W.

Health Aff (Millwood). 2017 Dec;36(12):2212. doi: 10.1377/hlthaff.2017.1392. No abstract available.

PMID:
29200360
20.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J, White K, SenGupta D, Cheng A, Quirk E.

Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31.

PMID:
28867499
21.

Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.

Pozniak A, Flamm J, Antinori A, Bloch M, Ward D, Berenguer J, Cote P, Andreatta K, Garner W, Szwarcberg J, Nguyen-Cleary T, McColl DJ, Piontkowsky D.

HIV Clin Trials. 2017 Jul;18(4):141-148. doi: 10.1080/15284336.2017.1338844. Epub 2017 Jul 9.

PMID:
28689453
22.

Acute Fluid Management of Large Burns: Pathophysiology, Monitoring, and Resuscitation.

Gillenwater J, Garner W.

Clin Plast Surg. 2017 Jul;44(3):495-503. doi: 10.1016/j.cps.2017.02.008. Epub 2017 Apr 14. Review.

PMID:
28576238
23.

Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.

Cornely OA, Leguay T, Maertens J, Vehreschild MJGT, Anagnostopoulos A, Castagnola C, Verga L, Rieger C, Kondakci M, Härter G, Duarte RF, Allione B, Cordonnier C, Heussel CP, Morrissey CO, Agrawal SG, Donnelly JP, Bresnik M, Hawkins MJ, Garner W, Gökbuget N; AmBiGuard Study Group.

J Antimicrob Chemother. 2017 Aug 1;72(8):2359-2367. doi: 10.1093/jac/dkx133.

24.

Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks.

Porter DP, Kulkarni R, Garner W, Miller MD, White KL.

Antivir Ther. 2017;22(6):495-502. doi: 10.3851/IMP3128. Epub 2017 Jan 16.

PMID:
28091393
25.

Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience.

McCullough M, Burg M, Lin E, Peng D, Garner W.

Burns. 2017 Feb;43(1):200-205. doi: 10.1016/j.burns.2016.07.026. Epub 2016 Aug 21.

PMID:
27554629
26.

Dual therapeutic functions of F-5 fragment in burn wounds: preventing wound progression and promoting wound healing in pigs.

Bhatia A, O'Brien K, Chen M, Wong A, Garner W, Woodley DT, Li W.

Mol Ther Methods Clin Dev. 2016 Jun 22;3:16041. doi: 10.1038/mtm.2016.41. eCollection 2016.

27.

Delayed-onset thrombocytopenia in a pediatric burn patient.

Kim J, Ho CH, Lewis KE, Garner WL, Chan RY.

Am J Hematol. 2016 Sep;91(9):958-60. doi: 10.1002/ajh.24443. Epub 2016 Jul 14. No abstract available.

28.

Protein Disulfide Levels and Lens Elasticity Modulation: Applications for Presbyopia.

Garner WH, Garner MH.

Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2851-63. doi: 10.1167/iovs.15-18413.

29.

Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.

Custodio JM, Fordyce M, Garner W, Vimal M, Ling KH, Kearney BP, Ramanathan S.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5135-40. doi: 10.1128/AAC.00005-16. Print 2016 Sep.

30.

Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.

Gallant J, Brunetta J, Crofoot G, Benson P, Mills A, Brinson C, Oka S, Cheng A, Garner W, Fordyce M, Das M, McCallister S; GS-US-292-1249 Study Investigators.

J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):294-298.

31.

Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials.

Garner W, White K, Szwarcberg J, McCallister S, Zhong L, Wulfsohn M.

Clin Infect Dis. 2016 Apr 1;62(7):929-934. doi: 10.1093/cid/civ1034. Epub 2015 Dec 21.

32.

Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.

van Lunzen J, Antinori A, Cohen CJ, Arribas JR, Wohl DA, Rieger A, Rachlis A, Bloch M, Segal-Maurer S, Garner W, Porter D, Bosse M, Piontkowsky D, Chuck SK, De-Oertel S.

AIDS. 2016 Jan;30(2):251-9. doi: 10.1097/QAD.0000000000000911.

PMID:
26684822
33.

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.

Wilkins EL, Cohen CJ, Trottier B, Esser S, Smith DE, Haas B, Brinson C, Garner W, Chuck S, Thorpe D, De-Oertel S.

AIDS Care. 2016;28(3):401-8. doi: 10.1080/09540121.2015.1096890. Epub 2015 Oct 21.

PMID:
26489045
36.

Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials.

Reeves I, Fisher M, Kegg S, Arribas J, Dau L, Garner W, Walker I, Nguyen T.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19807. doi: 10.7448/IAS.17.4.19807. eCollection 2014.

37.

Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis.

Arribas J, Rizzardini G, Arasteh K, Zurawski C, Dietz C, Pontani D, Garner W, Nguyen T.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19805. doi: 10.7448/IAS.17.4.19805. eCollection 2014.

38.

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis.

Stellbrink HJ, Antinori A, Pozniak A, Flamm J, Bredeek F, Patel K, Garner W, Piontkowsky D.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19793. doi: 10.7448/IAS.17.4.19793. eCollection 2014.

39.

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults.

Tashima K, Crofoot G, Tomaka FL, Kakuda TN, Brochot A, Vanveggel S, Opsomer M, Garner W, Margot N, Custodio JM, Fordyce MW, Szwarcberg J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19772. doi: 10.7448/IAS.17.4.19772. eCollection 2014.

40.

Comparability of weight loss reporting after gastric bypass and sleeve gastrectomy using BOLD data 2008-2011.

Sczepaniak JP, Owens ML, Shukla H, Perlegos J, Garner W.

Obes Surg. 2015 May;25(5):788-95. doi: 10.1007/s11695-014-1496-3.

PMID:
25394587
41.

I have seen the damage caused by rapid management turnover.

Garner W.

Nurs Stand. 2014 Sep 2;28(52):32. doi: 10.7748/ns.28.52.32.s36. No abstract available.

PMID:
25159968
42.

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.

Pozniak A, Markowitz M, Mills A, Stellbrink HJ, Antela A, Domingo P, Girard PM, Henry K, Nguyen T, Piontkowsky D, Garner W, White K, Guyer B.

Lancet Infect Dis. 2014 Jul;14(7):590-9. doi: 10.1016/S1473-3099(14)70796-0. Epub 2014 Jun 5.

PMID:
24908550
43.

Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.

Mills A, Crofoot G, Ortiz R, Rashbaum B, Towner W, Ward D, Brinson C, Kulkarni R, Garner W, Ebrahimi R, Cao H, Cheng A, Szwarcberg J.

HIV Clin Trials. 2014 Mar-Apr;15(2):51-6. doi: 10.1310/hct1502-51.

PMID:
24710918
44.

Donor-site preferences in women during autologous skin grafting.

Garcia E, Stone E, Chan LS, Van Vliet M, Garner WL.

Plast Reconstr Surg. 2014 Mar;133(3):378e-382e. doi: 10.1097/PRS.0000000000000062.

PMID:
24572883
45.

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.

Tashima K, Crofoot G, Tomaka FL, Kakuda TN, Brochot A, Van de Casteele T, Opsomer M, Garner W, Margot N, Custodio JM, Fordyce MW, Szwarcberg J.

AIDS Res Ther. 2014 Dec 1;11:39. doi: 10.1186/1742-6405-11-39. eCollection 2014.

46.

Cost-effectiveness comparison between topical silver sulfadiazine and enclosed silver dressing for partial-thickness burn treatment.

Sheckter CC, Van Vliet MM, Krishnan NM, Garner WL.

J Burn Care Res. 2014 Jul-Aug;35(4):284-90. doi: 10.1097/BCR.0b013e3182a36916.

PMID:
24121806
47.

Simulation of plastic surgery and microvascular procedures using perfused fresh human cadavers.

Carey JN, Rommer E, Sheckter C, Minneti M, Talving P, Wong AK, Garner W, Urata MM.

J Plast Reconstr Aesthet Surg. 2014 Feb;67(2):e42-8. doi: 10.1016/j.bjps.2013.09.026. Epub 2013 Sep 23.

PMID:
24094541
48.

Summary of the 2012 ABA Burn Quality Consensus conference.

Gibran NS, Wiechman S, Meyer W, Edelman L, Fauerbach J, Gibbons L, Holavanahalli R, Hunt C, Keller K, Kirk E, Laird J, Lewis G, Moses S, Sproul J, Wilkinson G, Wolf S, Young A, Yovino S, Mosier MJ, Cancio LC, Amani H, Blayney C, Cullinane J, Haith L, Jeng JC, Kardos P, Kramer G, Lawless MB, Serio-Melvin ML, Miller S, Moran K, Novakovic R, Potenza B, Rinewalt A, Schultz J, Smith H, Dylewski M, Wibbenmeyer L, Bessey PQ, Carter J, Gamelli R, Goodwin C, Graves T, Hollowed K, Holmes J 4th, Noordenbas J, Nordlund M, Savetamal A, Simpson P, Traber D, Traber L, Nedelec B, Donelan M, Baryza MJ, Bhavsar D, Blome-Eberwein S, Carrougher GJ, Hickerson W, Joe V, Jordan M, Kowalske K, Murray D, Murray VK, Parry I, Peck M, Reilly D, Schneider JC, Ware L, Singer AJ, Boyce ST, Ahrenholz DH, Chang P, Clark RA, Fey R, Fidler P, Garner W, Greenhalgh D, Honari S, Jones L, Kagan R, Kirby J, Leggett J, Meyer N, Reigart C, Richey K, Rosenberg L, Weber J, Wiggins B.

J Burn Care Res. 2013 Jul-Aug;34(4):361-85. doi: 10.1097/BCR.0b013e31828cb249. No abstract available.

PMID:
23835626
49.

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, Bloch M, Garner W, Guyer B, Williams S, Chuck S, Vanveggel S, Deckx H, Stevens M.

HIV Clin Trials. 2013 May-Jun;14(3):81-91. doi: 10.1310/hct1403-81.

PMID:
23835510
50.

Incorporation of fresh tissue surgical simulation into plastic surgery education: maximizing extraclinical surgical experience.

Sheckter CC, Kane JT, Minneti M, Garner W, Sullivan M, Talving P, Sherman R, Urata M, Carey JN.

J Surg Educ. 2013 Jul-Aug;70(4):466-74. doi: 10.1016/j.jsurg.2013.02.008. Epub 2013 Apr 30.

PMID:
23725934

Supplemental Content

Loading ...
Support Center